Latest News - Phase 3/4 Trials

Thursday, March 21, 2019

Biofrontera Reports Positive Phase 3 Results with Ameluz for PDT of AKs on Extremities and Trunk/Neck

Results for the primary endpoint of Biofrontera AG's Phase 3 clinical trial evaluating the safety and efficacy of conventional photodynamic therapy (PDT) with Ameluz and the BF-RhodoLED lamp for t…

Read the full story

Wednesday, March 13, 2019

Study: Port Wine Stain Laser Treatment Is Safe and Effective in Infants Without Anesthesia

Recent concerns about the repetitive use of general anesthesia in children younger than 3 have placed greater importance on the controversy surrounding the timing of port-wine stain laser treatme…

Read the full story

Monday, March 04, 2019

Almirall: Positive Data for KX2-391 for AKs; ThermiGen to be Divested

Results from two Phase III studies of KX2-391, also known as KX-01 ointment,  in the treatment of actinic keratosis show positive results. The findings have been presented at the 2019 Americ…

Read the full story

Friday, December 07, 2018

Naked Eye, Smart Phone Apps May Miss Melanomas

The naked eye alone is not enough to accurately diagnosis skin cancer and smart phone apps may also miss melanomas, according to a new review published in The Cochrane Library as part of a Special Col…

Read the full story

Tuesday, December 04, 2018

Phase 3 Data Positive for Revance's RT002

Long-acting neuromodulator daxibotulinumtoxinA for Injection (RT002) delivered positive top-line results in alleviating moderate to severe glabellar lines in the SAKURA 3 Phase 3 open-label, long-term…

Read the full story

Tuesday, October 23, 2018

LA BioMed Team to Study Treatments for Antibiotic-Resistant Skin Infections

Investigators from LA BioMed have scored a $5.3M grant from the National Institutes of Health to study the effectiveness of treatments for antibiotic-resistant skin infections. The study, Short and…

Read the full story

Thursday, October 11, 2018

Study: Positive Safety and Tolerability Results for Ortho Dermatologics' Altreno for Acne

Ortho Dermatologics shared results of two identical Phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel group studies examining the efficacy and safety of Altreno (tretinoin) …

Read the full story

Thursday, October 11, 2018

Galderma Ups Its Aesthetic R&D Game

Galderma Laboratories, L.P. is initiating six new Phase III and IV U.S. aesthetic clinical trials. The six newly initiated studies include three pivotal trials evaluating XpresHAn Technology p…

Read the full story

Tuesday, October 02, 2018

Ortho Dermatologics’ Bryhali Lotions Performs Well in Two Phase 3 Psoriasis Trials

Two Phase 3 randomized controlled trials show that Bryhali (halobetasol propionate) Lotion, 0.01%, an investigational potent to superpotent corticosteroid in the treatment of moderate-to-severe p…

Read the full story

Tuesday, September 18, 2018

FDA Clears Sebacia Microparticles for Laser-Based Acne Treatment

Sebacia Microparticles are now FDA-cleared for use in the treatment of acne. The clearance comes on the heels of a pivotal study demonstrating the clinical safety and efficacy of the micoparticles. Se…

Read the full story

Monday, September 17, 2018

UCB: Study Data for Cimzia and Bimekizumab Presented at EADV

UCB has presented new findings on Cimzia® (certolizumab pegol) and one of its key pipeline molecules, bimekizumab, for the treatment of moderate-to-severe chronic plaque psoriasis (PSO), along wit…

Read the full story

Wednesday, September 12, 2018

Foamix: Positive Topline Phase 3 Results for Topical Minocycline Foam

Foamix Pharmaceuticals’ FMX101 topical minocycline foam for the treatment of moderate-to-severe acne has met primary endpoints of its third Phase 3 clinical trial. Foamix shared topline resul…

Read the full story

Tuesday, August 21, 2018

MC2 Therapeutics Reports Positive Topline Data for Investigational Topical for Psoriasis

MC2-01 Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) from MC2 Therapeutics A/S achieved its primary and secondary endpoints, according to recently reported top-line data from…

Read the full story

Thursday, July 26, 2018

Almirall: Phase 3 Studies of KX2-391 for AK Meet Primary Endpoints

Both Phase 3 studies of KX2-391met the primary endpoint of complete clearance of actinic keratosis (AK) lesions at day 57 within the face or scalp treatment areas, Almirall, SA reports. Each study ach…

Read the full story

Monday, July 02, 2018

XELJANZ Receives EU Marketing Authorization for Adults with Active PsA

The European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis (PsA) in adul…

Read the full story
Load More